As for patients with triple-negative (three receptors negative, including ER, PR and HER2) and HER2-positive (human epidermal growth factor receptor 2) early BC, a neoadjuvant therapy might be optional (Huang & Yin, 2018). Here, ERBB2 is linked to breast cancer.